#United States #New York #Class Action #Gross Law Firm #Sarepta Therapeutics

Class Action Filed Against Sarepta Therapeutics, Inc.

On August 21, 2025, The Gross Law Firm announced a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ: SRPT), notifying shareholders who acquired shares during a specific period to consider their eligibility to participate. This lawsuit highlights allegations of material misrepresentation regarding the safety and efficacy of their gene therapy product, ELEVIDYS, which is aimed at treating Duchenne muscular dystrophy.

Background of the Allegations

Shareholders who purchased shares of Sarepta during the class period from June 22, 2023, to June 24, 2025, are specifically encouraged to reach out to the firm to discuss their rights. The core allegations of the complaint indicate that Sarepta's executives might have issued false or misleading statements concerning the safety of ELEVIDYS, a gene therapy intended as a treatment for patients suffering from Duchenne muscular dystrophy. Notably, it is claimed that serious side effects were not properly disclosed, and trial protocols failed to adequately assess these risks.

The lawsuit posits the following critical points:
1. Safety Concerns: ELEVIDYS was reported to pose significant safety risks that were not communicated to investors.
2. Ineffective Protocols: Trial regimes were allegedly inadequate in detecting severe adverse effects from the treatment.
3. Regulatory Scrutiny: Resulting from these safety issues, the company may have had to cease recruitment for trials and potentially faced increased scrutiny from regulatory bodies.
4. Misleading Statements: The executives' positive statements were made without a reasonable basis, leading to misinformation among investors.

Importance of Participation

The deadline for shareholders to join the class action is set for August 25, 2025. This date is crucial for investors who are considering being part of the legal proceedings, as it represents the limitation period for their potential claims. The Gross Law Firm stresses that participating does not require one to be appointed as a lead plaintiff, so shareholders can join without the associated obligation. They will also receive continuous updates through a portfolio monitoring service during the case's lifecycle.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a nationally recognized class action law firm dedicated to protecting the rights of investors impacted by malpractice and fraudulent activities. Their commitment lies not only in harming recovery when false statements inflate a company's stock but also in urging corporations to adhere to ethical business practices. The firm’s holistic approach enables them to navigate complex legal frameworks and advocate for affected investors effectively.

For those interested in joining this class action, the process is straightforward. Interested parties can register their details online through the provided link. Given the repercussions of potential malpractices by Sarepta Therapeutics, affected shareholders may have an avenue to potentially recover losses incurred due to these deceptive practices.

Contact Information

To inquire about joining the lawsuit or to get more information on their legal standing, shareholders can contact The Gross Law Firm using the following details:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th floor, New York, NY 10018

For further updates and guidance, shareholders can also check The Gross Law Firm's website for ongoing communications regarding this and similar cases. Don’t miss the opportunity to protect your investments and hold corporations accountable for their actions.